To date, the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has determined 399,600,607 cases and 5,757,562 …

Over the past several decades, messenger RNA (mRNA) vaccines have progressed from a
scepticism-inducing idea to clinical reality. In 2020, the COVID-19 pandemic catalysed the …

A drawback of the current mRNA-lipid nanoparticle (LNP) COVID-19 vaccines is that they
have to be stored at (ultra) low temperatures. Understanding the root cause of the instability …

In December 2019, a new and highly pathogenic coronavirus emerged—coronavirus
disease 2019 (COVID-19), a disease caused by severe acute respiratory syndrome …

As mRNA vaccines became the frontrunners in late-stage clinical trials to fight the COVID-19
pandemic, challenges surrounding their formulation and stability became readily apparent …

Recent medical advances have exploited the ability to address a given disease at the
underlying level of transcription and translation. These treatment paradigms utilize nucleic …

There is an urgent need for vaccines against coronavirus disease 2019 (COVID-19)
because of the ongoing SARS-CoV-2 pandemic. Among all approaches, a messenger RNA …

During the last two decades, there has been broad interest in RNA-based technologies for
the development of prophylactic and therapeutic vaccines. Preclinical and clinical trials have …

The remarkable impact of mRNA vaccines on mitigating disease and improving public
health has been amply demonstrated during the COVID-19 pandemic. Many new mRNA …

Abstract The CVnCoV (CureVac) mRNA vaccine for severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2) was recently evaluated in a phase 2b/3 efficacy trial in …